

# Supporting Information


Wu et al. 10.1073/pnas.0906547106

## SI Materials and Methods


**Antibodies, Reagents, and Plasmids.** The anti-Ubc13 antibody was from Zymed, and the antibodies for ERK1 (K-23) and  $\beta$ -catenin (H-102) were from Santa Cruz Biotechnology Inc. Fluorescence-labeled antibodies for mCD4-Pacific Blue (L3T4), mCD8-APC-Cy7 (53-6.7), mCD25-PE (PC61.5), CD44-FITC (IM7), B220-PE-Cy5.5 (RA3-6B2), CD43-PE (S7), CD19-PE-Cy7 (1D3), CD93-APC (AA4.1), Mac-1-APC-Cy7 (M1/70), Gr-1-PerCP-Cy5.5 (RB6-8C5), c-Kit<sup>-</sup>APC-Cy7 (2B8), Sca-1<sup>-</sup>APC (D7), CD45.1-FITC (A20), CD45.2-PE (104),  $\beta$ -catenin-FITC were from eBioscience. The streptavidin-PerCP-Cy5.5 and mouse lineage panel (559971) antibodies and the Annexin-V FITC Apoptosis Detection Kit I were from BD Biosciences.

**Flow Cytometry Analyses and Cell Sorting.** Single-cell suspensions were prepared from the thymus, peripheral blood, spleen, lymph


nodes, and bone marrow. After lysis of RBCs, the cell suspensions were filtered through nylon mesh, stained with fluorescence-labeled antibodies, and subjected to flow cytometry essentially as described (36) using a LSR II flow cytometer and the FlowJo analyzing software (Treestar). For  $\beta$ -catenin intracellular staining, the surface-stained cells were fixed and permeabilized using the Cytotfix/Cytoperm buffer (BD Biosciences) and then stained with  $\beta$ -catenin-FITC, followed by washing with the Perm/Wash buffer (BD Biosciences). For cell sorting, total bone marrow cells were stained with mouse lineage mixture (BD Biosciences) followed by incubation with anti-biotin microbeads (Miltenyi Biotec). Lineage negative cells were first purified by MACS sorting, and then stained for IL-7R, Sca-1, and c-Kit. LSK (Lin<sup>-</sup>IL-7R<sup>-</sup>Sca-1<sup>+</sup>c-Kit<sup>+</sup>), B220<sup>+</sup>, and myeloid (Gr-1<sup>+</sup>Mac-1<sup>+</sup>) cells were sorted using BD FACS Aria.




**Fig. S1.** Thymic atrophy in *Ubc13* iKO mice. Control and *Ubc13* iKO mice were prepared by poly(I:C) injection, as described in *Materials and Methods*. (A) Appearance of freshly isolated thymus from control and iKO mice showing the reduced size of the *Ubc13* iKO thymus. (B) H&E staining of thymus sections (magnification,  $\times 20$ ). Data are representative of three control and three iKO mice. (C) Total thymocyte numbers in control and iKO mice ( $n = 3$  each). Data are presented as mean  $\pm$  SD. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .




**Fig. S2.** Bone marrow atrophy in Ubc13 iKO mice. Control and Ubc13 iKO mice were prepared as described in *Materials and Methods*. (A) Appearance of bones (containing the femur and tibia) from age-matched control and Ubc13 iKO mice [9 days after initial poly(I:C) injection]. Data are representative of three control and three iKO mice. (B) H&E staining of femur sections derived from age-matched control and Ubc13 iKO mice, showing the loss of nucleated cells in the iKO bone marrow. Data are representative of three control and three iKO mice.




**Fig. S3.** Cell-intrinsic function of Ubc13 in hematopoiesis. Bone marrow cells from Ubc13<sup>+/+</sup> control (CD45.1<sup>+</sup>) and Ubc13<sup>fl/fl</sup>Mx1-Cre<sup>+</sup> (CD45.2<sup>+</sup>) mice were mixed in a 1:1 ratio and adoptively transferred into lethally irradiated Ubc13<sup>+/+</sup> recipient mice (CD45.1<sup>+</sup>CD45.2<sup>+</sup>) as described in *Materials and Methods*. After 6 weeks, the chimeric mice were either not treated (NT) or subjected to three consecutive poly(I:C) injections [Poly(I:C)] and subjected to bone marrow flow cytometry assays 9 days after the initial poly(I:C) injection. (A) Flow cytometry analysis of bone marrow myeloid cells based on expression of Gr-1 and Mac-1. Numbers indicate percentages of myeloid cells (Gr-1<sup>+</sup>Mac-1<sup>+</sup>) within total bone marrow cells (left). The gated myeloid cells were further analyzed based on their expression of CD45 congenital markers to separate into control and Ubc13 iKO populations (right). (B) Percentage of bone marrow B cells was analyzed based on B220 expression (Left) and further separated into CD45.1 (control) and CD45.2 (Ubc13 iKO) populations (right). (C) Percentage of LK and LSK bone marrow progenitor cells were analyzed as described in Fig. 4A (left) and further separated into CD45.1<sup>+</sup> (control) and CD45.2<sup>+</sup> (iKO) populations (right). Data are representative of three nontreated and three poly(I:C)-treated chimeric mice.



**Fig. S4.** Reciprocal bone marrow adoptive transfer.  $Ubc13^{fl/fl}Mx1-Cre^{-}$  (control) and  $Ubc13^{fl/fl}Mx1-Cre^{+}$  (iKO) mice (five mice/group) were lethally irradiated twice at the dose of 600cGy with 6-h interval and used as recipients. After 12 h, the irradiated mice were adoptively transferred with 5 millions of bone marrow cells from nonirradiated control or iKO mice. Six weeks later, both groups of the recipient mice were subjected to three consecutive intra-peritoneal polyIC injections. At day 9 after the first polyIC injection, thymocytes and bone marrow cells were isolated and stained with appropriate antibodies to analyze thymocyte development (A) and hematopoiesis phenotypes (B). The numbers in the squares indicate the percentages of different cell subsets. LK and LSK are defined as  $Lin^{-}IL-7R^{-}Sca-1^{-}c-Kit^{+}$  and  $Lin^{-}IL-7R^{-}Sca-1^{+}c-Kit^{+}$  progenitor cells, respectively.



**Fig. S5.** Real-time RT-PCR analyses of Wnt target gene expression in different populations of bone marrow cells. Control (CtI) and Ubc13 iKO mice were generated by polyIC injection, as described in *Materials and Methods*, and used for bone marrow cell preparation. LSK cell (A), B cell (B), and myeloid cell (C) populations were isolated by flow cytometric cell sorting and subjected to RNA preparation and real-time RT-PCR assays. Data are presented as fold relative to the control samples (arbitrarily set to 1) and are representative of three independent experiments.



**Fig. S6.** Flow cytometry analysis of intracellular  $\beta$ -catenin level. Control mice ( $Ubc13^{+/fl}Mx1-Cre^{+}$ ) were either left untreated or injected with PolyIC as described in *Materials and Methods*. Bone marrow cells were intracellularly stained with anti- $\beta$ -catenin or an isotype control as well as with antibodies for surface markers. Flow cytometry was performed to detect  $\beta$ -catenin intracellular level in gaited LK and LSK cell populations. Comparison was visualized by overlay of histogram of untreated and polyIC-treated mice. Data are representative of three independent experiments.